freshspring_325 t1_jda131q wrote on March 22, 2023 at 10:14 PM

Reply to comment by Next-Mobile-9632 in Phase 1 study: New medicine extends terminally-ill cancer patients' lives. Seventy percent of the patients who tested the medicine were stable after six weeks. Twelve continued the medication and were stable for 18 weeks. One woman took the medication for 17 months, and was stable for over two years by Wagamaga

Unfortunately, that really depends on the cancer type, stage, and treatment history. Progression-free survival for 5 months is actually an improvement for some patient populations.